These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 12196360

  • 1. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
    [Abstract] [Full Text] [Related]

  • 2. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W, Zhao J, Wang C, Wang T, Xing Y.
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    J Clin Oncol; 2001 Jan 15; 19(2):414-9. PubMed ID: 11208833
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
    Zinzani PL, Gandolfi L, Broccoli A, Argnani L, Fanti S, Pellegrini C, Stefoni V, Derenzini E, Quirini F, Baccarani M.
    Cancer; 2011 Mar 01; 117(5):1010-8. PubMed ID: 20960498
    [Abstract] [Full Text] [Related]

  • 7. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G.
    Blood; 1999 Jul 15; 94(2):429-33. PubMed ID: 10397709
    [Abstract] [Full Text] [Related]

  • 8. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL, Huang B, Lee EY, Chan WK, Kwong YL.
    J Nucl Med; 2014 Jun 15; 55(6):911-6. PubMed ID: 24819420
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J, Qiao W, Wang C, Wang T, Xing Y.
    Hematology; 2007 Oct 15; 12(5):423-30. PubMed ID: 17852456
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.
    Int J Radiat Oncol Biol Phys; 2012 Aug 01; 83(5):e647-54. PubMed ID: 22607911
    [Abstract] [Full Text] [Related]

  • 12. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2004 Jan 01; 31(1):22-8. PubMed ID: 14574514
    [Abstract] [Full Text] [Related]

  • 13. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O.
    Ann Hematol; 2006 Nov 01; 85(11):759-67. PubMed ID: 16871391
    [Abstract] [Full Text] [Related]

  • 14. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
    Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN.
    Leuk Lymphoma; 2000 Nov 01; 39(5-6):543-53. PubMed ID: 11342337
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G.
    Oncotarget; 2016 Dec 13; 7(50):83544-83553. PubMed ID: 27835875
    [Abstract] [Full Text] [Related]

  • 16. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
    Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD.
    J Clin Oncol; 2005 Jul 20; 23(21):4652-61. PubMed ID: 15837965
    [Abstract] [Full Text] [Related]

  • 17. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, Pötzi C, Raderer M, Dudczak R, Kletter K.
    Leukemia; 2002 Feb 20; 16(2):260-7. PubMed ID: 11840293
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.
    Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, Thomas J, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Blood; 2003 Jul 01; 102(1):53-9. PubMed ID: 12609836
    [Abstract] [Full Text] [Related]

  • 19. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Br J Haematol; 2001 Nov 01; 115(2):272-8. PubMed ID: 11703321
    [Abstract] [Full Text] [Related]

  • 20. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma.
    Zijlstra JM, Hoekstra OS, Raijmakers PG, Comans EF, van der Hoeven JJ, Teule GJ, Jonkhoff AR, v Tinteren H, Lammertsma AA, Huijgens PC.
    Br J Haematol; 2003 Nov 01; 123(3):454-62. PubMed ID: 14617005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.